GI
ALDX icon

GAMMA Investing’s Aldeyra Therapeutics ALDX Stock Holding History

GAMMA Investing’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$682 Sell
320
-797
-71% -$1.37K ﹤0.01% 3941
2026
Q1 		$1.89K Buy
1,117
+820
+276% +$3.59K ﹤0.01% 3683
2025
Q4 		$1.54K Sell
297
-757
-72% -$3.89K ﹤0.01% 3675
2025
Q3 		$5.5K Buy
1,054
+663
+170% +$3.46K ﹤0.01% 3138
2025
Q2 		$1.5K Sell
391
-293
-43% -$757 ﹤0.01% 3459
2025
Q1 		$3.93K Buy
+684
New +$4.04K ﹤0.01% 3180
2024
Q4 		– Sell
-25
Closed -$135 – 3779
2024
Q3 		$135 Buy
+25
New +$119 ﹤0.01% 3546

Other funds holding ALDX

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's ALDX Position: Q2 2026 in Review

GAMMA Investing reduced its Aldeyra Therapeutics (ALDX) stake by 71% in Q2 2026, selling an estimated $1.37K and leaving 320 shares worth $682. The position accounts for ﹤0.01% of the portfolio, ranked #3941.

GAMMA Investing first reported a position in ALDX in Q3 2024 and has held it in 7 quarters since. The position peaked at $5.5K in Q3 2025. 10 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • GAMMA Investing held 320 shares of Aldeyra Therapeutics worth $682 as of Q2 2026.
  • GAMMA Investing sold 797 Aldeyra Therapeutics shares in Q2 2026, an estimated $1.37K.
  • Aldeyra Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3941 holding.
  • GAMMA Investing first reported a position in Aldeyra Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • GAMMA Investing's Aldeyra Therapeutics position peaked at $5.5K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.